Keyphrases
Pregnancy Rate
100%
Polycystic Ovary Syndrome
61%
IVF Cycles
56%
In Vitro Fertilization
54%
Implantation Rate
49%
Gonadotropins
48%
Ovulation Induction
44%
In Vitro Fertilization-embryo Transfer (IVF-ET)
40%
Follicle-stimulating Hormone
40%
Intracytoplasmic Sperm Injection
39%
Gonadotropin-releasing Hormone
38%
Infertility
34%
Oocyte Retrieval
33%
Infertile Women
28%
Zygote Intrafallopian Transfer
28%
High-quality Embryo
28%
Ovarian Stimulation
28%
In Vitro Fertilization Cycle
26%
Pregnancy Outcome
25%
Fertilization Rate
25%
Cycle Outcomes
24%
Clomiphene Citrate
24%
Follicle
24%
Oocyte number
23%
Infertility Treatment
22%
Intrauterine Insemination
22%
Hysterosalpingography
20%
Frozen Embryo Transfer
20%
Controlled Ovarian Stimulation
20%
Human Chorionic Gonadotropin
19%
Embryo Transfer
17%
Male Factor Infertility
17%
Ovarian Response
17%
Assisted Reproductive Technology
17%
Laparoscopy
17%
Treatment Outcome
17%
Luteal Phase Support
17%
Recurrent Implantation Failure
17%
Estradiol
16%
Live Birth Rate
16%
Embryo Quality
16%
Natural Cycle
16%
Pelvic Inflammatory Disease
16%
Hormone Levels
15%
Treatment Choice
15%
Multiple Pregnancy
15%
Antral Follicle Count
15%
Human Ovary
14%
In Vitro Maturation
14%
Tubal Factor Infertility
14%
Medicine and Dentistry
In Vitro Fertilisation
97%
Oocyte
86%
Pregnancy Rate
83%
Polycystic Ovary Syndrome
61%
Embryo Transfer
60%
Follitropin
49%
Intracytoplasmic Sperm Injection
47%
Gonadotropin-Releasing Hormone
40%
Gonadotropin
34%
Embryo Quality
34%
Oocyte Retrieval
32%
Fertilization
31%
Diethylstilbestrol
30%
Follicle
26%
Clomifene Citrate
24%
Ovulation Induction
24%
Luteal Phase
23%
Intrauterine Insemination
21%
Systematic Review
21%
Zygote Intrafallopian Transfer
21%
Hysterosalpingography
21%
Controlled Ovarian Hyperstimulation
19%
Ovulation
18%
Laparoscopic Surgery
18%
Birth Rate
16%
Messenger RNA
15%
Antral Follicle
15%
Assisted Reproduction
15%
Multiple Pregnancy
15%
In Vitro
15%
Progesterone
15%
Conception
14%
Clomifene
14%
In Vitro Maturation
14%
Hysterectomy
14%
Hormone Therapy
14%
Receptor
14%
Prevalence
12%
Gonadorelin Antagonist
11%
Gonadorelin Agonist
11%
Supplementation
10%
Ovary Insufficiency
10%
Gonadorelin Derivative
10%
Abortion Rate
10%
Human Menopausal Gonadotropin
10%
Chorionic Gonadotropin
10%
Spontaneous Abortion
10%
Cesarean Section
9%
Luteal Support
9%
Oral Contraceptive Agent
9%